Agreed - the $50M looks to be the catalsy for share price drop. Although, as a micro-biotech company I would say this turned out to be a positive looking back. Trying to raise $50M in these markets + sector would be virtually impossible with their pipeline and no completion yet. The warchest is good through 2024 to complete trials, can only hope for positive results from trial.

Only difference I can tell is pharagrade vs. biological for GW/jazz. No reliance on botanical source can make it more pure and consistent? Easier to manufactur and distribute?